Nika Pharmaceuticals Financials
This page shows Nika Pharmaceuticals (NIKA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Recurring losses are being financed by outside capital while liabilities overwhelm NIKA’s limited asset base.
Across FY2023 and FY2025, cash conversion remained close to reported net loss, indicating that operating deficits were largely cash deficits rather than mainly non-cash accounting charges. In FY2025, financing cash flow of$79.5M nearly offset operating cash flow of-$79.7M , showing that operations required fresh capital to keep cash from falling faster.
By FY2025, liabilities reached
Short-term coverage weakened: the current ratio fell from 0.2x in FY2023 to 0.1x in FY2025. Cash also declined from
Financial Health Signals
Nika Pharmaceuticals does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Nika Pharmaceuticals passes 0 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Nika Pharmaceuticals reported a net loss of $76K while operations used $80K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nika Pharmaceuticals reported -$76K in net income in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Nika Pharmaceuticals held $2K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
NIKA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0 | $0 | $0 | $0 | N/A |
| SG&A Expenses | N/A | $53K+50.8% | $35K-45.7% | $65K | N/A | N/A | N/A |
| Operating Income | N/A | -$76K | N/A | -$65K | N/A | N/A | N/A |
| Net Income | N/A | -$76K | N/A | -$65K | N/A | N/A | N/A |
| EPS (Diluted) | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NIKA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $21K+17.1% | $18K-8.5% | $20K+2168.1% | $864+116.5% | $399-75.2% | $2K |
| Current Assets | $21K+17.1% | $18K-8.5% | $20K+2168.1% | $864+116.5% | $399-75.2% | $2K |
| Cash & Equivalents | $2K-9.3% | $2K-89.4% | $20K+2168.1% | $864+116.5% | $399-75.2% | $2K |
| Total Liabilities | $319K+33.2% | $239K+135.1% | $102K+459.7% | $18K-24.3% | $24K+128.4% | $11K |
| Current Liabilities | $319K+33.2% | $239K+135.1% | $102K+459.7% | $18K+72.8% | $11K | N/A |
| Total Equity | -$298K-34.5% | -$221K-169.3% | -$82K-374.4% | -$17K+26.7% | -$24K-165.2% | -$9K |
| Retained Earnings | -$9.0M-0.9% | -$8.9M-162.6% | -$3.4M-1.9% | -$3.3M-2298.7% | $152K+10.7% | $137K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NIKA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$69K | -$80K | N/A | -$65K | N/A | N/A | N/A |
| Financing Cash Flow | $56K | $79K | N/A | $84K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NIKA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Assets | -363.9% | N/A | -330.9% | N/A | N/A | N/A |
| Current Ratio | 0.070.0x | 0.07-0.1x | 0.19+0.1x | 0.050.0x | 0.04 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$298K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Nika Pharmaceuticals Ranks
Frequently Asked Questions
Is Nika Pharmaceuticals profitable?
No, Nika Pharmaceuticals (NIKA) reported a net income of -$76K in fiscal year 2025.
What is Nika Pharmaceuticals's operating cash flow?
Nika Pharmaceuticals (NIKA) recorded an outflow of $80K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nika Pharmaceuticals's total assets?
Nika Pharmaceuticals (NIKA) had $21K in total assets as of fiscal year 2025, including both current and long-term assets.
What is Nika Pharmaceuticals's current ratio?
Nika Pharmaceuticals (NIKA) had a current ratio of 0.07 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Nika Pharmaceuticals's return on assets (ROA)?
Nika Pharmaceuticals (NIKA) had a return on assets of -363.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Nika Pharmaceuticals's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Nika Pharmaceuticals (NIKA) held $2K in cash, cash equivalents and investments, and reported an operating cash outflow of $80K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Nika Pharmaceuticals's debt-to-equity ratio negative or not reported?
Nika Pharmaceuticals (NIKA) has negative shareholder equity of -$298K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nika Pharmaceuticals's Piotroski F-Score?
Nika Pharmaceuticals (NIKA) has a Piotroski F-Score of 0 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nika Pharmaceuticals's earnings high quality?
Nika Pharmaceuticals (NIKA) reported a net loss of $76K while operations used $80K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.